ALT
Altimmune, Inc.NASDAQHealthcare$3.34+7.05%ClosedMarket Cap: $294.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.49
P/S
7168.21
EV/EBITDA
-3.19
DCF Value
$0.08
FCF Yield
-23.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-36387.8%
Operating Margin
-230461.0%
Net Margin
-214861.0%
ROE
-49.4%
ROA
-31.5%
ROIC
-35.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $26.0K | 100.0% | $-28.9M | $-27.4M | $-0.27 | — |
| FY 2025 | $41.0K | -173.2% | $-94.5M | $-88.1M | $-1.00 | — |
| Q3 2025 | $5.0K | -299100.0% | $-20.9M | $-19.0M | $-0.21 | — |
| Q2 2025 | $5.0K | 100.0% | $-22.9M | $-22.1M | $-0.27 | — |
| Q1 2025 | $5.0K | 100.0% | $-21.8M | $-19.6M | $-0.26 | — |
| Q4 2024 | $5.0K | 100.0% | $-24.9M | $-23.2M | $-0.33 | — |
| FY 2024 | $20.0K | 100.0% | $-103.2M | $-95.1M | $-1.34 | — |
| Q3 2024 | $5.0K | 100.0% | $-24.8M | $-22.8M | $-0.32 | — |
| Q2 2024 | $5.0K | 100.0% | $-26.7M | $-24.6M | $-0.35 | — |
| Q1 2024 | $5.0K | -2040.0% | $-26.8M | $-24.4M | $-0.34 | — |
| Q4 2023 | $37.0K | 100.0% | $-33.6M | $-31.6M | $-0.54 | — |
| FY 2023 | $426.0K | 100.0% | $-95.9M | $-88.4M | $-1.66 | — |